Canine parvovirus nucleic acid fluorescence detection method based on endonuclease recognition
Through the fluorescence detection method based on endonuclease recognition, combined with RPA isothermal amplification and fluorescent probe hybridization, the problems of low sensitivity and complex operation in CPV detection were solved, and fast and convenient viral nucleic acid detection was achieved, reaching 95% Diagnostic accuracy and reduce detection costs.
Patent Information
- Application Number
- CN202411222985.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
AI Technical Summary
The existing technology has problems such as low sensitivity, high cost, complex operation and easy contamination in the detection of canine parvovirus (CPV). Moreover, the targeted sequence screening of CRISPR/Cas12 and Cas13 technologies is complex and complex, making it difficult to achieve rapid and convenient. Sensitive viral nucleic acid detection.
Using CPV nucleic acid fluorescence detection method based on endonuclease recognition, RPA isothermal amplification, fluorescent probe hybridization and endonuclease specific cleavage, combined with the visual display of fluorescent reader and colloidal gold test strip, it achieves fast and convenient Viral nucleic acid test.
It realizes ultra-sensitive and rapid detection of CPV viruses, the detection time is completed within 1 hour, the diagnostic accuracy of clinical samples reaches 95%, does not require expensive reagents and instruments, and has high specificity and high sensitivity.
Smart Images

Figure CN118996005A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pathogenic microorganism nucleic acid detection, and in particular to a detection method for canine parvovirus nucleic acid by RPA isothermal amplification, fluorescent probe hybridization, endonuclease specific cleavage and visual display. Background Art
[0002] Canine Parvovirus (CPV) is a highly contagious virus that has a strong ability to infect puppies and dogs with low immunity. It has a short incubation period and spreads quickly. Once infected, it can cause severe gastroenteritis and even endanger life.
[0003] The genome of CPV consists of single-stranded DNA and contains genes encoding capsid protein (VP) and non-structural protein (NS). The icosahedral symmetric capsid protein structure gives the virus strong resistance and transmission capabilities. It can resist a variety of environmental factors and evolve rapidly under the attack of the host immune system, allowing it to persist in nature. In addition, CPV can also insert genes from other viruses, such as canine adenovirus, to further enhance its pathogenicity. At present, no specific drug has been found to completely cure CPV infection, and early treatment is crucial to controlling the spread of the virus and improving the cure rate. Therefore, rapid and accurate diagnosis of CPV is of great significance for the prevention, control and treatment of the disease.
[0004] Traditional CPV detection methods, such as virus isolation, have disadvantages such as low sensitivity, high cost, and complex operation. Ultrasensitive detection methods, such as real-time quantitative PCR (qPCR), require expensive equipment and professional operators. In recent years, isothermal amplification technologies, such as loop-mediated isothermal amplification (LAMP), recombinant polymerase amplification (RPA), cross-primer amplification (CPA), etc., have been widely used in the field of virus detection due to their rapidity, high efficiency, simple operation, and high sensitivity. However, these technologies also have limitations such as poor specificity and easy contamination.
[0005] In recent years, CRISPR / Cas12 and Cas13 technologies have shown great potential in the field of CPV detection due to their advantages such as high efficiency, high specificity and programmability. Combining the rapid amplification capability of isothermal amplification technology with the specific recognition and cutting function of CRISPR / Cas technology can achieve rapid, convenient and sensitive viral nucleic acid detection and has been widely used. However, this method also has some shortcomings, such as easy contamination, complex target sequence screening, and complex operation. Therefore, it is crucial to establish a new nucleic acid detection method for the prevention and control of CPV. Summary of the invention
[0006] The purpose of the present invention is to provide a CPV nucleic acid fluorescence detection method based on nuclease recognition to solve the problems existing in the above-mentioned prior art.
[0007] To achieve the above object, the present invention provides the following scheme:
[0008] The invention provides a method for quickly separating DNA from CPV. The method comprises mixing a sample and a phosphate buffer solution (PBS) in a test tube at a ratio of 1:1, then boiling the test tube in boiling water for 5 minutes, centrifuging the test tube in a 4°C high-speed centrifuge at 10,000 rpm for 5 minutes, and collecting a supernatant containing DNA released by the virus.
[0009] The present invention provides an RPA primer for specifically recognizing CPV. The RPA primer has a length of 30 bp, a GC content of 40-60%, an amplification product length of 200±30 bp, and is composed of upstream and downstream primers as shown in SEQ ID N0.1.
[0010] The present invention also provides an RPA isothermal amplification system for detecting CPV, the total volume of the system is 50 μL, including 2×Reaction Buffer 25 μL, 10×Basic E-mix 5 μL, 2 μL each of RPA-F and RPA-R primers with a concentration of 10 μM of the above-mentioned SEQID N0.1, 5 μL of dNTPs, 20×CoreReaction Mix 2.5 μL, and then 2.5 μL of 280 mM MgOAc and 1 μL of virus lysate supernatant are added to the reaction system in sequence, and the reaction is carried out at 37° C. for 20 minutes.
[0011] The present invention also provides a nucleic acid endonuclease recognition system for detecting CPV, wherein the nucleic acid hybridization system is 23.5 μL, including 3 μL of RPA amplification product, 2 μL of 10 nM fluorescent probe, 2 μL of 10×NE Buffer, and 16.5 μL of RNase-free water.
[0012] The nucleotide sequence of the fluorescent probe is a complementary sequence of the conserved region sequence of the VP2 gene of CPV, with a length of 46 bp, and contains 2-3 mismatched or missing bases in the middle of the sequence as shown in SEQ ID No. 2. The N-terminus of the fluorescent probe is modified with 6-FAM, and the C-terminus is modified with BHQ1 (the result is read by a fluorescence reader) or Biotin (the result is displayed by a colloidal gold test paper).
[0013] The reaction conditions of the nucleic acid hybridization system are as follows: react at 95°C for 5 minutes, react at 95-85°C and decrease by 2°C / s, react at 85-25°C and decrease by 0.1°C / s, and then stop the reaction at 12°C. Finally, add 1.5uL of 10U T7EⅠ / Cruiser endonuclease and react at 37°C for 10 minutes.
[0014] The method for determining whether the sample to be tested contains CPV is to place the reaction tube with the nuclease T7EⅠ / Cruiser in a fluorescence reader with a constant temperature function of 37°C. If the result is positive after 10 minutes, it indicates that the sample contains CPV.
[0015] The method for judging whether the sample to be tested contains CPV is to insert the colloidal gold test paper into the reaction tube after the reaction is completed. If there is a red stripe on the T line within 10 minutes, it indicates that the sample contains CPV.
[0016] Based on the above technical scheme, the present invention has the following technical effects:
[0017] Based on the specific recognition of the nuclease T7EⅠ / Cruiser, the present invention has developed an ultra-sensitive, rapid, fluorescent detection method for CPV that does not require expensive reagents and instruments. The method includes the establishment of an RPA isothermal rapid amplification system, specific hybridization of fluorescent probes, recognition and enzyme cleavage of T7EⅠ / Cruiser, and the use of a fluorescent reader to capture fluorescent signals or immunological test paper for color development. The method achieves accurate detection of 1 copy of the CPV virus within 1 hour, and the diagnostic accuracy of clinical samples reaches 95%. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0019] Figure 1 The invention is the principle of a CPV nucleic acid fluorescence detection method based on nuclease recognition.
[0020] Figure 2 The binding and restriction sites of RPA primers and mutant fluorescent probes designed for the VP2 gene of CPV.
[0021] Figure 3 The fluorescence reader detection results of the CPV nucleic acid fluorescence detection system based on nuclease recognition, wherein 1 is the negative control sample, 2 is the positive control sample, 3 is the T7EⅠ enzyme digestion identification sample, and 4 is the Cruiser enzyme digestion identification sample.
[0022] Figure 4The colloidal gold test paper test results of the CPV nucleic acid fluorescence detection system based on nuclease recognition, where 1 is the negative control sample, 2 is the positive control sample, 3 is the T7EⅠ enzyme digestion identification sample, and 4 is the Cruiser enzyme digestion identification sample.
[0023] Figure 5 The specific detection results of the CPV nucleic acid fluorescence detection method based on the recognition of nuclease T7EⅠ. Among them, in the fluorescence reader and colloidal gold test paper, 1 is the CDV sample, 2 is the CCV sample, 3 is the CPIV sample, and 4 is the CPV sample.
[0024] Figure 6 The sensitivity test results of the CPV nucleic acid fluorescence detection method based on the recognition of nuclease T7EⅠ. Among them, C- is the RNase-free water sample, C+ is the CPV sample, and 1-8 is 1×10 7 copies / μL—1 copy / μL of pcDNA3.1-VP2 plasmid sample.
[0025] Figure 7 is the clinical sample diagnosis result of the CPV nucleic acid fluorescence detection method based on nuclease T7EⅠ recognition. Among them, C- is RNase-free water sample, C+ is 1×10 4 copies / μL of pcDNA3.1-VP2 plasmid samples, and 1-20 were clinical samples suspected of CPV. DETAILED DESCRIPTION
[0026] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0027] Example 1
[0028] Establishment of a fluorescence detection method for CPV nucleic acid based on endonuclease recognition ( Figure 1 ), the following describes the operation steps of the method by taking the detection of the VP2 gene of CPV as an example:
[0029] 1. Design and Synthesis of Probes and Primers
[0030] By comparing and analyzing the conserved region of the VP2 gene of CPV in GenBank (GenBank: OR667804.1), RPA primers and corresponding dual fluorescent DNA probes were designed and synthesized. Figure 2 ), the nucleic acid sequences of primers and probes are shown below, wherein the bold underlined sequence in the probe nucleic acid sequence is the mutation site, the original sequence is before the dividing line / , and the mutant sequence is after the dividing line / , which was synthesized by Sangon (Shanghai) Co., Ltd.
[0031] CPV-RPA-F:GCTATGAGATCTGAGACATTGGGTTTTTTAT
[0032] CPV-RPA-R:CTGTAGCAAATTCATCACCTGTTCTTAGTA
[0033] CPV-probe:TTTGTTGGTGTGCCACTAGTTCCA GT / CC ATGAGATGGTATT AATGTTC
[0034] That is, the original sequence:
[0035] CPV-probe:TTTGTTGGTGTGCCACTAGTTCCAGTTGAGATGGTATTAATG TTC
[0036] Mutation sequence:
[0037] CPV-probe:TTTGTTGGTGTGCCACTAGTTCCACCATGAGATGGTATTAAT GTTC
[0038] 2. CPV Virus DNA Extraction
[0039] Mix the sample and PBS buffer in a test tube at a ratio of 1:1, then boil the test tube in boiling water for 5 minutes, quickly place it in a 4°C high-speed centrifuge and centrifuge it at 10,000 rpm for 5 minutes. The collected supernatant contains the DNA released by the virus.
[0040] 3.RPA reaction system
[0041] The total volume of the RPA system was 50 μL, including 2×Reaction Buffer 25 μL, 10×Basic E-mix 5 μL, 2 μL of each of the RPA-F and RPA-R primers of the above SEQ ID N0.1 at a concentration of 10 μM, 5 μL of dNTPs, and 2.5 μL of 20×CoreReactionMix. Subsequently, 2.5 μL of 280 mM MgOAc and 1 μL of virus lysate supernatant were added to the reaction system in sequence, and the reaction was carried out at 37° C. for 20 min.
[0042] 4. Nucleic Acid Hybridization
[0043] The nucleic acid hybridization system is 23.5 μL, including 3 μL of RPA amplification product, 2 μL of 10 nM fluorescent probe, 2 μL of 10×NE Buffer, and 16.5 μL of RNase-free water.
[0044] The reaction conditions of the nucleic acid hybridization system are as follows: react at 95°C for 5 minutes, decrease the temperature by 2°C / s at 95-85°C, decrease the temperature by 0.1°C / s at 85-25°C, and then stop the reaction at 12°C. Finally, add 1.5uL of T7EⅠ / Cruiser with 10U of endonuclease and react at 37°C for 10 minutes.
[0045] The method for determining whether the sample to be tested contains CPV is to place the reaction tube with the nuclease T7EⅠ / Cruiser in a fluorescence reader with a constant temperature function of 37°C. If the result is positive after 10 minutes, it indicates that the sample contains CPV. If the result is negative, it indicates that the sample does not contain CPV. Figure 3 ).
[0046] Another method to determine whether the sample contains CPV is to insert the colloidal gold test paper into the reaction tube after the reaction is completed. If there is a red stripe on the T, C or T line within 10 minutes, it indicates that the sample contains CPV. If there is no red stripe on the T line, it indicates that the sample does not contain CPV ( Figure 4 ).
[0047] Example 2
[0048] The effect of a CPV nucleic acid fluorescence detection method based on nuclease recognition is determined. The following also describes the operation steps of the method by taking the detection of the VP2 gene of CPV as an example:
[0049] 1. Design and Synthesis of Probes and Primers
[0050] By comparing and analyzing the conserved regions of the VP2 gene of CPV in GenBank (GenBank: OR667804.1), CDS primers, RPA primers, qPCR primers and corresponding dual fluorescent DNA probes were designed and synthesized. Figure 2 ), the nucleic acid sequences of all primers and probes are shown below. They were synthesized by Sangon (Shanghai) Co., Ltd.
[0051] CPV-CDS-F:ATGAGTGATGGAGGAGTTCA
[0052] CPV-CDS-R:TTTCTAGGTGCTAGTTGAGA
[0053] CPV-RPA-F / R is as shown in the CPV-RPA-F / R sequence in Example 1.
[0054] CPV-qPCR-F:ATGCCATTTACTCCAGCAGCTATGAGATCT
[0055] CPV-qPCR-R:ATAAAATGTTCCTGTAGCAAATTCATCACC
[0056] CPV-probe is shown as the CPV-probe sequence in Example 1.
[0057] 2. Construction of VP2 standard plasmid
[0058] The gene sequence was amplified using 2 μL CPV viral DNA and CPV-CDS primers according to the instructions of 2×Taq Master Mix (P111-01, Nanjing Novogene Biotech Co., Ltd.). The amplified PCR product was connected to the pcDNA3.1 vector, and the pcDNA3.1-VP2 plasmid was extracted after transformation of DH5α receptor cells, culture of bacterial solution, and sequencing to confirm correctness.
[0059] The original DNA concentration of pcDNA3.1-VP2 was determined using NanoDrop ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA) and converted into viral copy number, which was then diluted to 1 × 10 8 copies / μL.
[0060] 3. Viral DNA or RNA Extraction
[0061] Methods The DNA or RNA of canine parvovirus (CPV), canine distemper virus (CDV), canine coronavirus (CCV), and canine parainfluenza virus (CPIV) were extracted according to the instructions of StarSpin Rapid Viral DNA or RNA Kit (P144-01, Beijing Kangrun Chengye Biotechnology Co., Ltd.).
[0062] 4. Reverse transcription of RNA viruses
[0063] Methods The RNA of RNA viruses was reverse transcribed into cDNA according to the instructions of HiScript II First-Strand cDNA Synthesis Kit (R212-01, Nanjing Novozymes Biotech Co., Ltd.).
[0064] 5. Specificity determination of CPV nucleic acid fluorescence detection method based on nuclease recognition
[0065] The DNA / cDNA extracted from CPV, CDV, CCV, and CPIV were used as templates respectively, and the isothermal rapid amplification of RPA, the specific binding of the fluorescent probe, the recognition and enzyme cleavage of T7EⅠ in Example 1 were carried out. At the same time, the fluorescent signal was captured by a fluorescent reader or the immunological test paper was used for color development to detect the specificity of the method.
[0066] The test results showed that only samples with CPV were positive, and samples with other viruses were negative ( Figure 5 ), indicating that the detection method is specific.
[0067] 6. Sensitivity determination of CPV nucleic acid fluorescence detection method based on nuclease recognition
[0068] The concentration was 1×10 8 The pcDNA3.1-VP2 plasmid was diluted 10-fold in a gradient manner, 1×10 7 copies / μL, 1×10 6 copies / μL, 1×10 5 copies / μL, 1×10 4 copies / μL, 1×10 3 copies / μL, 1×10 2 copies / μL, 1×10 copies / μL, 1 copy / μL, and different concentrations of plasmid were used as templates.
[0069] The detection method of the present invention is carried out according to Example 1. After the reaction is completed, a fluorescence reader is used to capture the fluorescence signal or an immunological test paper is used to colorimetrically interpret the result to determine the minimum copy number that can be detected by the detection method.
[0070] The test results showed that the detection limit of this method was 1copy( Figure 6 ), indicating that the detection method is sensitive.
[0071] 7. Clinical sample determination based on the CPV nucleic acid fluorescence detection method based on nuclease recognition
[0072] The collected 20 suspected CPV samples were mixed with PBS buffer in a test tube at a ratio of 1:1, and then the test tube was placed in boiling water for 5 minutes, and then quickly placed in a 4°C high-speed centrifuge and centrifuged at 10,000 rpm for 5 minutes to collect the supernatant.
[0073] According to the reaction system: 10 μL 2×ChamQ Universal SYBR qPCR Master Mix, 1 μL (10 μmol / L) upstream and downstream primers, 1 μL sample supernatant, ddH2O supplemented to 20 μL for qPCR reaction.
[0074] The qPCR reaction procedure was 3 minutes of pre-denaturation at 98°C, 35 cycles of denaturation at 98°C for 10 seconds, annealing at 56°C for 30 seconds, and extension at 72°C for 15 seconds, and finally a final extension at 72°C for 10 minutes to terminate the reaction. The negative / positive status of the sample was determined by the fluorescence curve of qPCR.
[0075] Meanwhile, the detection method of the present invention is carried out according to Example 1, and after the reaction is completed, a fluorescence reader is used to capture the fluorescence signal or an immunological test paper is used to colorimetrically interpret the result to determine whether the sample is negative or positive.
[0076] The results of the fluorescence reader showed that there were 15 positive samples and 5 negative samples. Compared with the qPCR test, the accuracy was 100%. The results of the colloidal gold test paper showed that there were 14 positive samples and 6 negative samples. Compared with the qPCR test, the accuracy was 95% ( Figure 7 ).
[0077] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the ideas and principles of the present invention should be included in the protection scope of the claims of the present invention.
[0078] SEQ ID NO.1
[0079] CPV-RPA-F565:5'-GCTATGAGATCTGAGACATTGGGTTTTTTAT-3'
[0080] CPV-RPA-R790:5'-CTGTAGCAAATTCATCACCTGTTCTTAGTA-3'
[0081] SEQ ID NO.2
[0082] CPV-probe:5'-TTTGTTGGTGTGCCACTAGTTCCA GT / CC ATGAGATGGTA TTAATGTTC-3'.
Claims
1. A method for detecting canine parvovirus nucleic acid by fluorescence based on endonuclease recognition, Features: The detection method comprises extracting canine parvovirus DNA, using RPA primers that specifically identify canine parvovirus, performing RPA recombinase polymerase amplification, and performing nucleic acid hybridization experiments. Then, the specific recognition and cutting ability of the nuclease T7EⅠ / Cruiser is utilized, combined with fluorescent probe hybridization technology, to perform visual detection of canine parvovirus nucleic acid, thus providing a new idea for rapid diagnosis of viral diseases.
2. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 1, Features: The RPA primers that specifically identify canine parvovirus are 30 bp in length, have a GC content of 40-60%, and have an amplified product length of 200±30 bp, which is composed of the upstream and downstream primers shown in SEQID N0.
1.
3. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 2, Features: The total volume of the RPA isothermal amplification system is 50 μL, including 2×Reaction Buffer 25 μL, 10×Basic E-mix 5 μL, 2 μL of each of the RPA-F and RPA-R primers with a concentration of 10 μM of the above SEQ ID N0.1, 5 μL of dNTPs, and 2.5 μL of 20×CoreReaction Mix. Subsequently, 2.5 μL of 280 mM MgOAc and 1 μL of virus lysate supernatant were added to the reaction system in sequence, and the reaction was carried out at 37° C. for 20 min.
4. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 3, Features: The nucleic acid hybridization system is 23.5 μL, including 3 μL of RPA amplification product, 2 μL of 10 nM fluorescent probe, 2 μL of 10×NE Buffer, and 16.5 μL of RNase-free water.
5. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 4, Features: The nucleotide sequence of the fluorescent probe is a complementary sequence to the conservative region sequence of the VP2 gene of canine parvovirus, has a length of 46 bp, and contains 2-3 mismatched or missing bases in the middle of the sequence as shown in SEQ ID N0.
2.
6. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 4, Features: The N-terminus of the fluorescent probe is modified with 6-FAM, and the C-terminus is modified with BHQ1 for reading the result by a fluorescence reader or with Biotin for displaying the result by a colloidal gold test paper.
7. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 4, Features: The reaction conditions were as follows: 5 min at 95°C, 2°C / s at 95-85°C, 0.1°C / s at 85-25°C, and then 12°C to stop the reaction. Finally, 1.5 μL of 10 U of endonuclease T7EⅠ / Cruiser was added and the reaction was allowed to proceed at 37°C for 10 min.
8. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 7, Features: The method for judging whether the sample to be tested contains canine parvovirus is to place the reaction tube with the nuclease T7EⅠ / Cruiser in a fluorescence reader with a constant temperature function of 37°C. If the result is positive after 10 minutes, it indicates that the sample contains canine parvovirus.
9. The method for canine parvovirus nucleic acid fluorescence detection based on endonuclease recognition according to claim 7, Features: The method for judging whether the sample to be tested contains canine parvovirus is to insert the colloidal gold test paper into the reaction tube after the reaction is completed. If there is a red band on the T line within 10 minutes, it indicates that the sample contains canine parvovirus.
